SCENIC BIOTECH
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severe diseases.
SCENIC BIOTECH
Industry:
Biometrics Biotechnology Collaborative Consumption Life Science
Founded:
2017-01-01
Address:
Amsterdam, Noord-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.scenicbiotech.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
37.6 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
EnteroBiotix
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
ONI
ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.
SpyBiotech
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.
Current Advisors List
Current Employees Featured
Founder
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Series A - Scenic Biotech
Inkef
Inkef investment in Series A - Scenic Biotech
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - Scenic Biotech
EIR Ventures
EIR Ventures investment in Series A - Scenic Biotech
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series A - Scenic Biotech
BioMedPartners
BioMedPartners investment in Series A - Scenic Biotech
Netherlands Enterprise Agency
Netherlands Enterprise Agency investment in Grant - Scenic Biotech
Oxford University Innovation
Oxford University Innovation investment in Series A - Scenic Biotech
BioGeneration Ventures
BioGeneration Ventures investment in Series A - Scenic Biotech
Oxford Science Enterprises
Oxford Science Enterprises investment in Series A - Scenic Biotech
Official Site Inspections
http://www.scenicbiotech.com Semrush global rank: 6.8 M Semrush visits lastest month: 783
- Host name: server024.yourhosting.nl
- IP address: 185.37.71.31
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Scenic Biotech"
About - Scenic Biotech
Our robust pipeline, derived from our proprietary Cell-seq™️ platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic …See details»
Scenic Biotech - Crunchbase Company Profile & Funding
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors. View contacts for Scenic Biotech to access new leads and connect with decision-makers.See details»
Scenic Biotech Company Profile 2024: Valuation, …
Developer of a genomics and immunotherapy technology designed to assist in the development of disease-modifying therapeutics for rare genetic disorders and other illnesses.See details»
Scenic Biotech - LinkedIn
Our robust pipeline, derived from our proprietary Cell-seq™️ platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders.See details»
Careers - Scenic Biotech
We are ambitious and entrepreneurial, with an experienced management team, and are bolstering our drug discovery and development capabilities to advance our expanding pipeline and accelerate compounds towards the clinic and to …See details»
Scenic Biotech - Oxford Science Enterprises
Scenic Biotech is a pre-clinical biotech company using their proprietary platform technology to identify novel drug targets based on genetic modifiers for patients with rare diseases and cancers.See details»
Scenic Biotech Enters Into Genetic Modifier …
Sep 21, 2020 Scenic Biotech refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV. For further information please …See details»
Scenic Biotech Enters into Research Collaboration with Bristol …
AMSTERDAM, April 30, 2024--Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration …See details»
Platform - Scenic Biotech
Scenic Biotech has overcome the technical challenges of reliably finding genetic modifiers or the “hidden disease protection factors” using Cell-Seq, its unique discovery platform. This has resulted in a rapidly growing pipeline of novel …See details»
Scenic Biotech Raises $31 Million to Advance Pipeline …
Mar 10, 2022 European investors Eir Ventures, BioMedPartners, and Vesalius Biocapital led the financing, with participation by existing investors Inkef Capital, BioGeneration Ventures, and Oxford Science Enterprises, together with …See details»
Scenic Biotech Announces Positive Preclinical Data for its QPCTL ...
Dec 9, 2023 Scenic Biotech Oscar Izeboud, PhD, CEO Phone: +31 6 51 06 27 97 Email: [email protected] Trophic Communications Desmond James & Priscillia …See details»
Scenic Biotech Appoints Jens Würthner as Chief Medical Officer
Oct 24, 2022 AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the …See details»
Scenic Biotech Enters Into Genetic Modifier Collaboration With ...
Sep 21, 2020 Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach Utilises Scenic’s unique Cell-Seq …See details»
Scenic Biotech Announces $31 Million Financing to Progress …
Mar 10, 2022 Alongside its in-house pipeline, Scenic has a multi-year, multi-indication strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and …See details»
Scenic Biotech enters into Research Collaboration with Bristol …
Apr 30, 2024 Bristol Myers Squibb gains access to Scenic’s Cell-Seq technology platform to unlock the underlying genetic interactions of cellular pathways for undisclosed targets Scenic …See details»
Scenic Biotech Announces $31 Million Financing to Progress …
Mar 10, 2022 Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases. Investment will accelerate Scenic Biotech’s transition …See details»
Pipeline - Scenic Biotech
Building on our exceptional understanding of metabolic pathways, we focus our internal pipeline on neuro and metabolic diseases with high unmet medical need. In our partnerships, we are …See details»
Scenic Biotech Announces Positive Preclinical Data for its QPCTL ...
Dec 9, 2023 AMSTERDAM, the Netherlands, December 09, 2023--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today …See details»
News - Scenic Biotech
News Release Scenic Biotech Enters Cooperative Research and Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann …See details»